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Abstract
Magnetic nanoparticle-based gene transfection has been shown to be an effective, non-viral technique for delivery of both
plasmid DNA and siRNA into cells in culture. It has several advantages over other non-viral delivery techniques, such as short
transfection times and high cell viability. These advantages have been demonstrated in a number of primary cells and cell
lines. Here we report that oscillating magnet array-based nanomagnetic transfection significantly improves transfection
efficiency in both human prenatal cardiac progenitor cells and adult cardiomyocytes when compared to static
magnetofection, cationic lipid reagents and electroporation, while maintaining high cell viability. In addition, transfection of
adult cardiomyocytes was improved further by seeding the cells onto Collagen I-coated plates, with transfection efficiencies
of up to 49% compared to 24% with lipid reagents and 19% with electroporation. These results demonstrate that oscillating
nanomagnetic transfection far outperforms other non-viral transfection techniques in these important cells.
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Introduction
The discovery, isolation and differentiation of human cardiac
progenitor cells from the epicardium of the heart has given
scientists and clinicians alike a tangible opportunity to investigate
cardiovascular diseases as well as other issues concerning tissue
regeneration [1,2,3,4]. Cardiac progenitor cells, with their ability
to differentiate into cardiomyocytes, fibroblasts and coronary
vessels in vitro, are unique in their ability to replace damaged
cardiac tissue in cardiovascular cell therapy [5,6]. The isolation of
primary adult human cardiomyocytes has made it possible to
formulate in vitro models to understand the human heart and
cardiac diseases [7], identify the different cardiomyocytes present
[8], and study cardiomyocyte differentiation to address tissue
regeneration [9]. However, despite these advances, successes in
cardiovascular gene therapy still remains elusive and non-viral
transfection of cardiomyocytes suffers from poor efficiency and
relatively low cell viability.
There are more than 3,000 genetic disorders that arise as a
result of single gene alterations. In the cardiovascular system
disorders such as atrioventricular conduction delay, atrial septal
defects, early valve calcification and endocardial cushion effect, all
involve single gene alterations [10]. Understanding these muta-
tions and their resulting disorders remains crucial in our search for
a cure. While it may be possible to identify a disease-causing gene,
delivery of genetic material into a cell to correct the defective gene
remains a challenge. Currently, this is achieved mostly by using
non-infective viruses, cationic lipid reagents and electroporation
in vitro (Table 1). Most gene delivery approaches are not been
widely applicable due to low transfection efficiency or the lack of
suitable vectors, target specificity, or safety issues arising from
translating the technique into humans [11].
In order to overcome these problems there is a critical need for
an efficient, biocompatible and remotely controllable method of
transfection. The use of magnetic nanoparticles (MNPs) has
numerous applications in the field of biomedicine such as targeted
drug delivery; diagnostics combined with therapeutics (i.e.
magnetic resonance-guided stem cells labelled with MNPs for cell
replacement therapy); MNP labelled-cell sorting; localised hyper-
thermia for the treatment of solid tumours, remote control of cell
processes, and external magnetic field mediated gene delivery
[12,13,14,15].
Nanomagnetic transfection is a non-viral gene delivery
technique that uses magnetic force acting on superparamagnetic
nanoparticles (SPIONs) onto which plasmid DNA or siRNA is
adsorbed. High gradient, rare earth magnets placed below the
culture plate direct the MNP/DNA complexes into contact with
cells and oscillating the magnet array induces endocytosis of the
complex, after which the DNA is released into the cytoplasm
[16,17]. The advantages of magnetofection in vitro are: 1) low
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amounts of transfection complexes; 2) high cell viability; 3) high
transfection efficiency; 4) little or no interference with cell
proliferation and differentiation [18,19,20,21,22,23,24]. Al-
though biocompatible MNPs have been developed specifically
for magnetofection in various cell types with a stationary
magnet array [19,23], there have been no reports of the use of
an oscillating magnet array during transfection of human
prenatal cardiac progenitor cells and adult cardiomyocytes.
Here we demonstrate the in vitro delivery of the reporter plasmid
pEGFP-N1 using the oscillating magnet array and MNPs in
human prenatal cardiac progenitor cells and adult cardiomyo-
cytes and compare it to other non-viral transfection techniques.
Materials and Methods
Cells and Reagents
Human prenatal cardiac progenitor cells (Cambridge Biosci-
ence, Cambridge, UK) and adult cardiomyocytes (Celprogen,
California, USA) were purchased, cultured and maintained in
standard tissue culture flasks containing horse serum supplement-
ed Cardiac Cellutions medium (Cambridge Bioscience, Cam-
bridge, UK) or in Extra Cellular Matrix (ECM) coated tissue
culture flasks (Celprogen, California, USA) containing human
cardiomyocytes cell culture complete media with serum and
antibiotics (Celprogen, California, USA). The pEGFP-N1 (Clon-
tech, California, USA), a 4.7 kb plasmid containing a CMV
promoter and gene expressing enhanced Green Fluorescent
Protein (eGFP) was used as a reporter for this study. The plasmid
Table 1. Review of methods used for transfecting cardiovascular system cells.
Cell type Source Transfection method Transfection efficiency
Cardiovascular system cells Chicken Adenoviral vector 63% [38]
Cardiomyocytes Rat Adenoviral vector 90% [39]
Cardiomyocytes Rat Adenoviral vector 100% [40]
Cardiomyocytes Rat Adeno associated viral vector 90% [40]
Cardiomyocytes Rat Adeno associated viral vector 88.1% [41]
Cardiomyocytes Rat Adenoviral-polylysine vector 70% [42]
Cardiomyocytes Rat Retrovirus/Lentiviral vector 70–100% [40]
Cardiomyocytes Rat Calcium phosphate precipitate 1–2% [40]
Cardiomyocytes Rat Calcium phosphate precipitate 5–8% [41]
Cardiomyocytes Rat Calcium phosphate precipitation method 2–4% [43]
Cardiomyocytes Rat Calcium phosphate precipitation method 5–10% [54]
Cardiovascular system cells Chicken Electroporation 26% [38]
Cardiomyocytes Rat Electroporation 7.5% [41]
Cardiomyocytes Rat Electroporation 37% [40]
Cardiomyocytes Rat Nucleofection 4.8% [41]
Cardiomyocytes Rat Nucleofection 70% [40]
Cardiomyocytes Rat Lipofectin 1.6% [42]
Cardiomyocytes Rat Lipofectamine 2000 8.1% [41]
Cardiomyocytes Rat Fugene 6 3.3% [41]
Cardiomyocytes Rat Optical transfection 5% [40]
Cardiovascular system cells Hamster Hypothermic-cardioplegia method 77.369.0% [44]
Cardiomycytes Rat Pressure mediated transfection 4865% [45]
Cardiomyocytes Pig Adenoviral vector [46]
Cardiomyocytes Rat Adeno associated viral vector [47]
Cardiac progenitor cells Mice Bicistronic lentiviral vector [48]
Cardiovascular system cells Dog Hemagglutinating virus of Japan-liposome method [49]
Cardiovascular system cells Rat Hemagglutinating virus of Japan–liposome method [50]
Cardiomyocytes Rat Liposomes coated with uv inactivated sendai viral vector [47]
Cardiomyocytes Rat Lipofectamine plus [41]
Cardiomyocytes Rat Geneporter [41]
Cardiomyocytes Rat Metafectene [41]
Cardiomyocytes Rat Lipogen [41]
Cardiovascular system cells Rat Ultrasound-targeted liposome microbubble destruction [51]
Cardiovascular system cells Dog DNA-polymer coating [52]
Cardiac progenitor cells Human The phiC31 integrase genomic modification system [53]
doi:10.1371/journal.pone.0069812.t001
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DNA was purified using EndoFree Plasmid Purification kit
(Qiagen, Crawley, UK) and maintained at 280uC in endonucle-
ase-free water (Sigma, Dorset, UK).
Adhesion Assay
As human adult cardiomyocytes are a semi-adherent cell type,
adhesion studies were performed. 96 well tissue culture plates
(Corning, New York, USA) were coated with foetal bovine serum
(FBS: 10, 5, 2.5, and 1.25%) (Lonza, Cologne, Germany),
polyethyleneimine (PEI: 10, 5, 2.5, 1.25, 0.6 and 0.3 mg/ml)
(Sigma, Dorset, UK), gelatin (0.1, 0.05 and 0.025% w/v) (Sigma,
Dorset, UK) and rat tail collagen I (1, 0.5, 0.25 and 0.125 mg/ml)
(Sigma, Dorset, UK), made up in phosphate buffer saline (PBS)
and incubated overnight at 4uC. Following incubation the coated
plates were washed once with PBS, 20,000 human adult
cardiomyocytes were seeded onto coated wells and incubated
overnight at 37uC with 5% CO2. 24 h post seeding, the wells were
washed twice with PBS and stained with 2 mg/ml nuclear
Hoechst-33342 stain (Sigma, Dorset, UK) at 1 ml per well. Cells
adhered per field were imaged and phenotypes were recorded.
Nanomagnetic Transfection
10,000 progenitor cells and 20,000 cardiomyocytes per well
were seeded into 96 well tissue culture plates previously coated
with 0.8 mg/ml rat tail collagen I, and onto extra cellular matrix
coated tissue culture treated 96 well plates (Celprogen, California,
USA) in 100 ml complete growth media and incubated for 24 h at
37uC with 5% CO2. Prior to transfection, 0.05 or 0.1 mg of
pEGFP-N1 formed complexes with 0.2 or 0.35 ml NeuroMag
(nanoTherics, Keele, UK) for 15 minutes in serum-free growth
media containing antibiotics (Celprogen, California, USA)
(Figure 1). NeuroMag, a MNP transfection vector was used for
its non-interference with proliferation and low cytotoxicity, as
observed during transfection of oligodendrocyte progenitor cells
[19] and neural precursor/stem cells [21,23]. After complex
formation, 80 ml of complete medium was added, mixed and
transferred, drop-wise, onto the appropriate well(s) containing
prenatal human cardiac progenitor cells or adult cardiomyocytes.
Plates were placed on a 96 well oscillating NdFeB (Rare earth
magnet, an alloy of neodymium, iron and boron) magnet array
following the magnefect nano II system protocol (Figure 1).
Following 30 minutes exposure to the oscillating magnetic array,
the culture plate was removed from the system and incubated at
37uC with 5% CO2 for 48 h. Lipofectamine 2000 (Invitrogen,
Paisley, UK) and Nucleofector 2b (Lonza, Cologne, Germany)
were evaluated for comparison and transfections were performed
according to the manufacturer’s instructions.
Cell Viability Assay
CytoTox-ONETM homogenous membrane integrity assay
(Promega, Southampton, UK) provided the measure of released
lactate dehydrogenase (LDH) through damaged membrane of
dead cells and the assay was performed according to manufactur-
er’s instruction. Fluorescence was recorded at excitation wave-
length 560 nm and emission wavelength 590 nm using a
fluorescent plate reader (BioTek, Bedfordshire, UK). Viability
data is expressed as a percentage using the following formula.
Percentage viability = 100– [1006(Experimental – Background
fluorescence)/(Maximum LDH release – Background fluores-
cence)].
Microscopy Analysis
48 h post transfection, cells were stained with 2 mg/ml
Hoechst-33342 (nuclear) stain at 1 ml per well to ensure that only
viable cells were counted while correlating GFP expressing cells.
Both GFP expression and Hoechst fluorescence was observed
using an epifluorescent microscope (Olympus IX51, Essex, UK). A
semi-quantitative analysis of transfection efficiency was deter-
mined by counting the number of GFP-expressing cells versus the
total number of Hoechst stained cells using the cell counting
feature of ImageJ software (National Institute of Health, USA).
Cell viability was determined by counting the number of
cellTraceTM calcein red-orange-AM (Invitrogen, Paisley, UK)
versus the total number of Hoechst stained cells and phase contrast
microscopic image of cells using ImageJ software. Statistical
significance was calculated using one-way analysis ANOVA with
Bonferroni’s multiple comparison test (GraphPad Prism v6.01,
California, USA).
Figure 1. Oscillating nano-magnetofection 96 well experimental setup (a) Diagrammatic representation of a 96 well oscillating
magnet array-based nanomagnetic transfection setup using NdFeB magnetic array.
doi:10.1371/journal.pone.0069812.g001
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Results
Oscillating Magnet Array-based Nanomagnetic
Transfection of Human Cardiac Progenitor Cells
In prenatal human cardiac progenitor cells approximately
18.665.2% transfection efficiency was observed when the
complexes were subjected to an NdFeB magnet array oscillating
at a frequency of 2 Hz with a displacement of 0.2 mm (Figure 2).
Different oscillating frequencies (0, 2 and 4 Hz) and displacements
(0.2, 0.4, 0.6 mm) were evaluated in order to ascertain their
impact. Initial results were improved to 21.366.8% transfection
efficiency using a magnet array oscillating at 4 Hz, with a 0.2 mm
displacement. This appeared to be the optimum frequency/
amplitude combination in this case and there was a decrease in
transfection efficiency when compared to 2 Hz/0.2 mm
(18.665.2%), 2 Hz/0.4 mm (19.263.3%, p.0.05) and 2 Hz/
0.6 mm (14.660.9%, p.0.05), 4 Hz/0.4 mm (15.564.5%), and
4 Hz/0.6 mm (13.064.8%, *p,0.05). The 4 Hz/0.2 mm group
also outperformed the no magnet control (5.563.2%, **p,0.001),
static magnetofection (14.964.4%), cationic lipid-based transfec-
tion (6.363.4%, ***p,0.001), and electroporation (15.263.8%)
(Figure 2). While there appears to be a suggestion of some
systematic variation in transfection efficiency with displacement at
4 Hz, the relationship is not statistically significant across all three
displacements and is not seen in the 2 Hz groups.
Cell Adhesion Assay
In the adhesion studies, cells adhered better to wells coated with
rat tail collagen I (0.125, 0.25, 0.5, 1 mg/ml), when compared to
gelatin from bovine serum (0.05, 0.1, 0.025% W/v), polyethyle-
neimine (0.6, 1.25, 0.3, 10, 5, 2.5 mg/ml) and foetal bovine serum
(1.25, 5, 2.5, 10% v/v). Morphologically, cells seeded onto
collagen I-,gelatin-, FBS- and un- coated wells were normal in
appearance, unlike cells seeded in polyethyleneimine-coated wells,
which, though adhering, they were rounded, gathered in clusters
with compacted nucleus and a high levels of cell debris were
observed. With the latter case, cells were also observed to detach
from the surface after washing (Figure 3). Cardiomyocytes being a
semi-adherent cell type, collagen I was found to be a suitable
coating to enhance adhesion in cardiomyocytes to aid adherent
state transfection.
Figure 2. Comparison of prenatal human cardiac progenitor cells transfected using oscillating magnet array-based nanomagnetic
transfection. (a) Fluorescent microscope images of prenatal human cardiac progenitor cells transfected with pEGFP-N1 representing each
conditions, took 48 h post transfection. (I) GFP fluorescence and Hoechst image for 2 Hz 0.2 mm, (II) GFP fluorescence and Hoechst image for 4 Hz
0.2 mm, (III) GFP fluorescence and Hoechst image for static magnetofectionTM, (IV) GFP fluorescence and Hoechst image for electroporation (V) GFP
fluorescence and Hoechst image for lipid based transfection reagent, (VI) GFP fluorescence and Hoechst image for un-transfected (b) Prenatal human
cardiac progenitor cells were transfected with pEGFP-N1 as indicated, and scored using manual counting using ImageJ software, 48 h after
transfection. Data shown are the media 6 SD. n = 12 for 4 Hz 0.2 mm. n = 9 for 2 Hz 0.2 mm and static conditions. n = 6 for 4 Hz 0.4 mm, 4 Hz
0.6 mm, no magnet, electroporation and pEGFP-N1 only electroporation conditions. n = 3 for 2 Hz 0.4 mm, 2 Hz 0.6 mm, pEGFP-N1 only, Neuromag
only, and un-transfected conditions. (*p,0.05, ***p,0.001 - Statistically significant).
doi:10.1371/journal.pone.0069812.g002
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Transfection of Human Adult Cardiomyocytes
Human adult cardiomyocytes were transfected using an
oscillating magnet array on the magnefect-nanoII system at a
frequency of 2 Hz with a 0.2 mm displacement. No difference in
transfection efficiency between the cells coated with Collagen I
(46.064.0%) and ECM (44.866.1%, p.0.05) coated plates was
observed. However, cells seeded onto uncoated plates exhibited
low transfection efficiency (22.764.2%, **p,0.01) compared to
the other conditions as shown in Figure 4. The results demonstrate
that oscillating magnetofection can transfect adherent cells
efficiently when compared to semi-adherent cells. Following this
we evaluated the oscillating nanomagnetic transfection technique
against another adherent state transfection and a suspension state
transfection methods i.e. lipid- and electroporation-based technol-
ogies.
Cardiomyocytes transfected using the oscillating magnet array
on the magnefect system at 4 Hz frequency/0.2 mm displacement
(TE= 48.862.8%) and at 2 Hz 0.2 mm (TE=44.6612.4%)
outperformed both a commonly used cationic lipid
(TE= 24.067.8%, ***p,0.001) and electroporation
(19.168.3%, ***p,0.001). At 4 Hz 0.2 mm (48.862.8%) and
2 Hz 0.2 mm (44.6612.4%)) conditions cardiomyocytes showed
significant increase in transfection efficiency when compared to no
magnet control (28.866.8%, p,0.001) as shown in Figure 5.
Overall these results demonstrate successful and efficient delivery
of gene into cardiomyocytes using an oscillating magnet array and
MNPs.
Cell Viability
Cell viability based on the CytoTox-ONETM homogenous
membrane integrity assay for human prenatal cardiac progenitor
cells was: static magnetofection (90.8610.4%); 2 Hz/0.2 mm
(84.4613.9%); and 4 Hz/0.2 mm (76.3625.0%); n = 3 for all
groups. The cell viability based on cellTraceTM calcein red-orange
AM staining for human adult cardiomyocytes was: no magnet
(92.862.3%); 2 Hz/0.2 mm (89.765.6%); and 4 Hz/0.2 mm
(69.568.4%); n= 9 for all groups. Overall the results demonstrate
that MNP-based gene delivery appears to have minimal impact on
the viability of cardiac progenitor cells and cardiomyocytes at
static and low frequencies, however, a decrease in viability with the
increasing frequency was observed.
Discussion
Recent studies have demonstrated that, in some cell types, the
use of oscillating magnet arrays on the magnefect system may
enhance nanomagnetic gene transfection in comparison to static
magnetofection [25,26,27]. It appears that cellular uptake of
Figure 3. Adhesion studies in adult human cardiomyocytes. (a) Light and Fluorescent microscope images of adult human cardiomyocytes
seeded onto different coatings, took after overnight incubation. (I) Light and Hoechst image for collagen 1 coating (0.125 mg/ml), (II) Light and
Hoechst image for gelatine coating (0.05% w/v), (III) Light and Hoechst image for polyethyleneimine coating (0.6 mg/ml), (IV) Light and Hoechst
image for foetal bovine serum coating (1.25%), and (V) Light and Hoechst image for no coating (b) adult human cardiomyocytes adhered per view as
indicated, and scored using manual counting using ImageJ software, post 16 PBS wash after overnight incubation in the corresponding coatings.
Data shown are the media 6 SD. n = 4 for all the conditions.
doi:10.1371/journal.pone.0069812.g003
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complexes during MNP mediated transfection is through endocy-
tosis [28], especially through caveolae-mediated endocytosis in
oscillating nanomagnetic gene transfection [16]. However, there
may be effects due to oscillations that occur after the complex has
been internalized that facilitate transfection.
Both cardiac progenitor cells and adult cardiomyocytes are
important cell types for studies of the genetic basis of heart
disorders such as atrioventricular conduction delay, atrial septal
defects, early valve calcification and endocardial cushion effect. In
order to understand these diseases and develop treatments, it is
necessary to develop efficient and safe gene transfection techniques
that also have the potential to be translated to the clinic. The
oscillating nanomagnetic transfection technology demonstrated
here outperforms other non-viral transfection techniques and, as
MNPs are in clinical use as MRI contrast agents, has the potential
to be translated into clinical application, such as transplantation of
genetically altered cells.
In this study, we have shown that it is possible to optimize
oscillating nanomagnetic transfection by investigating a range of
frequencies and amplitudes. Similar transfection studies using
oscillating nanomagnetic transfection on mouse embryonic fibro-
blasts, human umbilical vein endothelial cells [17], rat oligoden-
drocyte precursor cells [19], rat astrocytes [27], MG63 and NCI-
H292 cells [29,25] demonstrates the versatility of the frequency-
displacement based-nanomagnetic transfection technology as well
efficiency over a range of primary, differentiated, undifferentiated
cells and cell lines. The reason behind frequency-displacement
dependent transfection remains elusive; however, increased
cytosolic Ca2+ transients and enhanced Ca2+ oscillations have
been observed with increasing pacing frequency in adult mouse
myocytes [30]. Similarly, shear stress induced cytosolic Ca2+
transients are demonstrated in different cell types [31,32]. The
frequency-displacement dependent transfection we observe may
depend on the cytosolic Ca2+ oscillations, which is reported to
interfere with the transfection and gene expression of cells [33,34].
Moreover oscillating nanomagnetic transfection being an
adherent cell transfection technique, we have also demonstrated
that transfection efficiency can be enhanced by coating the wells
with collagen. It is likely that increased efficiency in cells seeded
onto rat tail collagen I was due to efficient adherence as collagen
type-I is one of the fibrous proteins within extracellular matrix
and, being a structural protein, it is highly biocompatible. In the
cardiomyocytes, this led to increased adhesion and improved
transfection efficiency with the oscillating system, while PEI and
foetal bovine serum coating had a detrimental effect on the cells.
This study represents a promising stepping stone towards a
valuable research tool for cardiac gene therapy.
Oscillating nanomagnetic transfection optimisation may also be
influenced by the properties of the MNPs used. While it is true that
increases in the magnetic content (volume of magnetic material) of
the particles will increase the magnetic force, generally the
particles used for these studies are iron oxide/polymer composite
Figure 4. Comparison of oscillating magnet array-based nanomagnetic transfection between adult human cardiomyocytes seeded
onto rat tail collagen 1 coated and ECM coated plates. (a) Fluorescent microscope images of adult human cardiomyocytes transfected with
pEGFP-N1 representing each conditions, took 48 hrs post transfection. (I) GFP fluorescence and Hoechst image for 2 Hz 0.2 mm in collagen 1 coated
(0.125 mg/ml) plate, (II) GFP fluorescence and Hoechst image for 2 Hz 0.2 mm in ECM coated plate, and (III) GFP fluorescence and Hoechst image for
2 Hz 0.2 mm in un-coated plate (b) adult human cardiomyocytes were transfected with pEGFP-N1 as indicated, and scored using manual counting
using Image J software, 48 h after transfection. Data shown are the media 6 SD. n = 3 for all the conditions. (**p,0.01- Statistically significant).
doi:10.1371/journal.pone.0069812.g004
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particles. Increasing the hydrodynamic diameter is not always
associated with a proportional increase in magnetic iron oxide as
the polymer represents the bulk of the particle’s volume. Previous
studies on MNP-mediated gene delivery has shown that 100 nm
MNPs (hydrodynamic diameter) were endocytosed through
caveolae-mediated endocytosis [16]; 200 nm MNPs through
clathrin- or caveolae-mediated endocytosis [35]; and 300 nm
MNPs through macropinocytosis and clathrin-mediated endocy-
tosis [36]. Receptor mediated endocytosis has been involved either
totally or partially in these demonstrated entry mechanisms of
different sized nanoparticles. A diameter of 50–60 nm is consid-
ered to be suitable for optimal receptor mediated endocytosis [37],
however the hydrodynamic diameter of Neuromag used in this
study ranges between 140–200 nm [27]. Clearly the magnetic
force on the particles, while important, is only one parameter to be
considered as different entry mechanisms may be associated with
increased or decreased transfection efficiency. Still, MNP-mediat-
ed gene delivery depends to some degree on the attractive force
exerted by the magnet array on the magnetic particles [25]. The
attractive force is directly proportional to the volume of magnetic
material in the particle, magnetic field strength/gradient of the
magnet array and magnetic properties (susceptibility) of the
particle [18]. Superparamagnetic nanoparticles have high mag-
netic susceptibility but are limited in size to diameters of roughly
30 nm or less for iron oxides (though this is somewhat dependent
on aspect ratios as magnetite has strong shape anisotropy).
Suitable biocompatible polymer coating/matrices are also impor-
tant for enhancing transfection, alongside size and magnetic
properties of the nanoparticles [28].
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Figure 5. Comparison of oscillating magnet array-based nanomagnetic transfection over lipid based transfection and
electroporation in adult human cardiomyocytes. (a) Fluorescent microscope images of adult human cardiomyocytes transfected with
pEGFP-N1 representing each conditions, took 48 h post transfection. (I) GFP fluorescence and Hoechst image for oscillating magnet array-based
nanomagnetic transfection performed at 2 Hz 0.2 mm, (II) GFP fluorescence and Hoechst image for oscillating magnet array-based nanomagnetic
transfection performed at 4 Hz 0.2 mm (III) GFP fluorescence and Hoechst image for lipid based transfection reagent, (IV) GFP fluorescence and
Hoechst image for electroporation and (V) GFP fluorescence and Hoechst image for untransfected (b) adult human cardiomyocytes were transfected
with pEGFP-N1 as indicated, and scored using manual counting using Image J software, 48 h after transfection. Data shown are the media 6 SD.
n = 18 for oscillating magnet array-based nanomagnetic transfection at 2 Hz 0.2 mm. n = 12 for lipid based transfection reagent. n = 6 for oscillating
magnet array-based nanomagnetic transfection at 4 Hz 0.2 mm, electroporation and pEGFP-N1 only electroporation conditions. n = 9 for no magnet.
n = 3 for pEGFP-N1 only, Neuromag only, and un-transfected conditions. (***p,0.001- Statistically significant).
doi:10.1371/journal.pone.0069812.g005
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